Significant elevation in PPL and PLEC staining in recurrent group 2 compared to group 1 (paclitaxel-treated and culled at the same time as control) and the control group (Fig. 4) was observed by immunohistochemistry, suggesting a potential link between PPL and PLEC expression, paclitaxel resistance and subsequent recurrence in ovarian cancer. The gene discussed is PPL; the disease is ovarian carcinoma.